Tower Research Capital (TRC)’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$34.9K Buy
10,315
+5,078
+97% +$23K ﹤0.01% 3443
2026
Q2
$24.4K Sell
5,237
-4,248
-45% -$23K ﹤0.01% 3373
2026
Q1
$54.4K Buy
9,485
+8,659
+1,048% +$61.4K ﹤0.01% 2670
2025
Q4
$8.2K Sell
826
-2,911
-78% -$26.6K ﹤0.01% 3963
2025
Q3
$24.8K Sell
3,737
-1,357
-27% -$6.56K ﹤0.01% 3106
2025
Q2
$20.5K Sell
5,094
-771
-13% -$2.54K ﹤0.01% 3668
2025
Q1
$20.4K Buy
5,865
+4,210
+254% +$18.6K ﹤0.01% 2944
2024
Q4
$10.9K Buy
1,655
+238
+17% +$1.88K ﹤0.01% 3768
2024
Q3
$12.8K Sell
1,417
-158
-10% -$1.88K ﹤0.01% 3561
2024
Q2
$25.3K Buy
1,575
+1,068
+211% +$15.5K ﹤0.01% 3614
2024
Q1
$7.95K Sell
507
-983
-66% -$15.4K ﹤0.01% 4108
2023
Q4
$20K Buy
+1,490
New +$18.5K ﹤0.01% 3646

Other funds holding LXEO

Tower Research Capital (TRC)'s LXEO Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Lexeo Therapeutics (LXEO) stake by 97% in Q3 2026, buying an estimated $23K and bringing the position to 10,315 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3443.

Tower Research Capital (TRC) first reported a position in LXEO in Q4 2023 and has held it in 12 quarters since. The position peaked at $54.4K in Q1 2026. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Tower Research Capital (TRC) held 10,315 shares of Lexeo Therapeutics worth $34.9K as of Q3 2026.
  • Tower Research Capital (TRC) bought 5,078 Lexeo Therapeutics shares in Q3 2026, an estimated $23K.
  • Lexeo Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3443 holding.
  • Tower Research Capital (TRC) first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Tower Research Capital (TRC)'s Lexeo Therapeutics position peaked at $54.4K in Q1 2026.
  • 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.